Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 6, 2026Circulation

Abstract TH822: Characteristics of Glucagon-like Peptide-1 Receptor Agonist Initiators and Temporal Trends in Prescriptions by Diabetes Status; MarketScan 2016-2023

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRob WalkerECEthan CannonFNFaye Norby

Discussion

Loading...

Member takes

Overview

MarketScan data reveals rising semaglutide prescriptions in diabetes, indicating shifts in obesity treatment strategies.

Key Points

  • To describe characteristics of GLP-1 RA users and document prescription trends by diabetes status from 2016 to 2023.
  • Analysis of MarketScan administrative claims databases (2016-2023)
  • Cohort construction of enrollees prescribed GLP-1 RAs
  • Assessment of diabetes status using Charlson Comorbidity Index and ICD-10-CM codes
  • 1,063,761 new GLP-1 RA users identified
  • 56% of enrollees had prevalent diabetes
  • Semaglutide prescriptions surpassed liraglutide since 2021
  • Tirzepatide prescriptions have rapidly increased since 2022

Cite This Study

Walker et al. (2026) studied this question.

synapsesocial.com/papers/69fa97ce04f884e66b531bbfhttps://doi.org/10.1161/cir.153.suppl_1.th822
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns2025 · 53 citations
  2. 2779-P: Clinical Characteristics and Treatment Patterns among Glucagon-Like Peptide Receptor Agonist (GLP-1RA) Users in a U.S. EHR and Claims Linked Database2024
  3. 3Trends in GLP ‐1 Receptor Agonist Prescribing Without an Apparent FDA ‐Approved Indication2026
  4. 41152-P: Treatment Trends in Youth-Onset Type 2 Diabetes—Changing Landscape after GLP-1RA Approval2024
  5. 5Trends in initiation of GLP-1 RA in patients with type 2 diabetes during 2014–2019: a US database study2021 · 9 citations